European Journal of Medicinal Chemistry p. 658 - 670 (2016)
Update date:2022-08-10
Topics:
Lepri, Susan
Goracci, Laura
Valeri, Aurora
Cruciani, Gabriele
Bosentan, the first-in-class drug used in treatment of pulmonary arterial hypertension, is principally metabolized by the cytochromes P450, and it is responsible for cytochromes induction and drug-drug interaction events with moderate to severe consequences. A strategy to reduce drug-drug interactions consists of increasing the metabolic stability of the perpetrator, and fluorinated analogues are often designed to block the major sites of metabolism. In this paper bosentan analogues were synthesized, and their metabolism and biological activity were evaluated. All synthesized compounds showed an improved metabolic stability towards CYP2C9, with one maintaining a moderate antagonist effect towards the ETA receptor.
View MoreJiangsu Hualin Chemical Co.,Ltd
Contact:86-25-87787395
Address:jiangsu china
Contact:86-21-57725962
Address:shanghai
shijiazhuang baisheng chem co.; ltd
Contact:86-0311-80790826
Address:shijiazhuang hebei
Nanjing lanbai chemical Co.,Ltd.
Contact:+86-25-85499326
Address:Room 908, 9F Taiyue Building,No.285 Heyan Road
website:http://www.herbpurify.com
Contact:0086-028-85249238
Address:Room709-C1,Incubator Building, Tianfu Life Science Park No.88,Keyuan Road,Gaoxin district,Chengdu City,Sichuan Prov,China
Doi:10.1002/anie.201203923
(2012)Doi:10.1002/ejoc.200500758
(2006)Doi:10.1016/j.tetlet.2007.11.029
(2008)Doi:10.1021/ja5081103
(2014)Doi:10.1002/asia.201601430
(2017)Doi:10.1016/S0040-4020(98)00140-9
(1998)